David Ricks, Eli Lilly CEO (Jeenah Moon/Bloomberg via Getty Images)

Up­dat­ed: Eli Lil­ly wins long-await­ed ap­proval for Alzheimer’s drug

Af­ter decades of try­ing to de­vel­op a treat­ment for Alzheimer’s dis­ease, Eli Lil­ly has fi­nal­ly won FDA ap­proval for its drug do­nanemab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.